
After myriad failures, a new wave of ALS drugs approaches
Few diseases have suffered more drug development disappointment than amyotrophic lateral sclerosis. Earlier this year, an experimental drug from Denali Therapeutics, and a candidate from Calico Life Sciences and AbbVie, failed in the clinic. The ALS …